Open AccessThe price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis
Author(s) -
Samuel B. Keller,
Davey M. Smith
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32834d3cab
Subject(s) - emtricitabine , medicaid , reimbursement , cost effectiveness , medicine , pharmacy , pre exposure prophylaxis , regimen , medical prescription , actuarial science , family medicine , business , health care , human immunodeficiency virus (hiv) , men who have sex with men , economics , pharmacology , viral load , risk analysis (engineering) , syphilis , antiretroviral therapy , economic growth